Hong Kong-listed innovative pharmaceutical company Grand Pharma (00512) has welcomed a new member to its global innovation product matrix — its associate company Sirtex Medical Pty Ltd has recently secured the FDA 510(k)-cleared Hourglass® embolization plug and related product assets. For Grand Pharma, this marks another move in the continuous global expansion of its interventional diagnosis and treatment product pipeline.
Public information shows that Hourglass® features a self-expanding nitinol braided mesh frame, with the proximal half covered by an ultra-thin PTFE membrane and the distal end anchored by a bare mesh. It leverages blood flow pressure to help the mesh conform to the vessel wall, and supports retrieval and repositioning before full deployment. The device is compatible with 6–8mm peripheral vessels, and its approved indications do not include aneurysm occlusion, with contraindications covering extremity mobile vessels and the pulmonary artery.
This design provides immediate vessel occlusion while helping to improve anchoring stability, reduce the risk of post-operative device migration, and give operators room for error when handling complex tortuous vascular anatomy. Taking a longer view, the addition of Hourglass® is merely the latest step in Grand Pharma's continued expansion across nuclear medicine oncology and cardio-cerebrovascular precision interventional diagnosis and treatment.
In April of this year, the company's flagship nuclear medicine product Yigan Tai® (yttrium[90Y] microsphere injection) successfully reached its clinical endpoint in the DOORwaY90 study conducted in the United States. The FDA had previously approved a new indication for unresectable HCC based on breakthrough interim data from that study, making it the world's first and only selective internal radiation therapy product approved by the FDA to cover both unresectable HCC and colorectal cancer liver metastases. Meanwhile, the LAVA® liquid embolic agent has been commercialized in the United States since October 2023 and continues to ramp up rapidly.
From nuclear medicine to embolization devices, the dense兑现 of a series of milestones is outlining Grand Pharma's strategic depth in high-barrier tracks.
The addition of the new embolization product is expected to create substantive procedural synergy with Yigan Tai®. Before performing yttrium-90 radioembolization, physicians often need to first use embolization devices to occlude collateral vessels such as the gastroduodenal artery, in order to prevent radioactive microspheres from flowing ectopically into the gastrointestinal tract and causing adverse reactions. With Hourglass® incorporated, Grand Pharma is expected to further cover a one-stop solution of "preoperative collateral occlusion plus intraoperative intratumoral radiotherapy," linking the two products from independent devices into consecutive steps within the same surgical procedure.
This synergy is not a simple叠加 but a product complement built around the actual pathway of interventional procedures. In the longer term, the indication boundaries of Hourglass® also imply new market space. Beyond tumor intervention, the product can be used in peripheral vascular malformations, trauma bleeding control, and other routine interventional scenarios, which is expected to drive the company's commercialization team to extend from tumor intervention departments to broader areas such as peripheral vascular disease and emergency hemostasis.
From access management to vascular embolization, Grand Pharma's precision interventional diagnosis and treatment product matrix continues to extend, and its platform-based布局 is becoming increasingly clear, providing more complete product support for the company's subsequent global commercialization of products.
This acquisition reflects Grand Pharma's continuously deepening overall globalization strategy — from the overseas clinical breakthrough of yttrium-90 microspheres and the commercialization of LAVA in the United States, to the incorporation of this globally mature embolization asset. Grand Pharma is continuously integrating global innovation resources, connecting overseas mature products to its own platform, and its ability to allocate innovative assets globally keeps improving as the company continues to implement its "Go Global" innovation development strategy.
In addition to its rich product pipeline, in global R&D, Grand Pharma has established extensive cooperation with leading global pharmaceutical companies, universities, and research institutions, providing front-end touchpoints for the identification, introduction, and transformation of innovative assets. At the same time, the company has established multiple R&D technology platforms and R&D centers to support the continued incubation and landing of more innovative products. In the nuclear medicine oncology segment, the company's Boston R&D center in the United States and its Chengdu radiopharmaceutical R&D center in China have respectively built a tumor intervention technology platform and an RDC technology platform.
In the first half of 2026, Grand Pharma had储备 34 innovative projects under research, with R&D investment of approximately HK$760 million, and recorded 18 major milestone progresses. On the registration side, the company's global clinical and "China-U.S. dual filing" registration system is becoming increasingly mature. Multiple products have obtained clinical approvals from international regulatory agencies, core product clinical results have been published in top international journals, and they have successively been included in authoritative diagnosis and treatment guidelines at home and abroad.
The capability accumulation from early discovery to international registration constitutes the infrastructure for the company to undertake global innovative assets. At the industrial chain level, the company has built full-chain capabilities covering "early discovery—preclinical research—registration filing—clinical development—commercialization." From the acquisition of innovative assets and the advancement of clinical registration to commercialization, Grand Pharma is linking the complete closed loop of innovation value with full industrial chain capabilities.
The incorporation of the Hourglass® asset is a concrete example of this closed loop: a mature device that has completed overseas clinical validation and crossed regulatory thresholds enters the company's product matrix through global resource integration, and then advances volume ramp-up by relying on existing channels and clinical networks, with each link closely connected and orderly linked.
From early positioning in high-barrier tracks, to building a global R&D and registration network, to continuously adding mature assets through innovation resource integration, Grand Pharma's forward-looking vision and strategic determination in industrial chain布局 run throughout. Looking ahead, Grand Pharma stated that it will continue to deepen its globalization innovation strategy, improve its full-chain R&D and commercialization system, accelerate the landing of innovative products, and provide more advanced and diverse treatment options for patients worldwide.